References
(1) M G Murphy, L M Plunkett, B J Gertz, et al (1998) MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism – Journal of Clinical Endocrinology & Metabolism, 1998 Feb, Volume 83 (Issue 2), Pages 320-5.
(2) R Nass, S S Pezzoli, M Clancy Oliveri, et al (2008) Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial – Annals of Internal Medicine, 2008 Nov 4, Volume 149 (Issue 9), Pages 601–611.
(3) J Svensson, C Ohlsson, J O Jansson, et al (1998) Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males – Journal of Bone and Mineral Research, 1998 Jul, Volume 13 (Issue 7), Pages 1158-66.
(4) M G Murphy, S Weiss, M McClung, et al (2001) Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women – Journal of Clinical Endocrinology & Metabolism, 2001 Mar, Volume 86 (Issue 3), Pages 1116-25.
(5) G Copinschi, R Leproult, A Van Onderbergen, et al (1997) Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man – Neuroendocrinology, 1997 Oct, Volume 66 (Issue 4), Pages 278-86.